Terapia resynchronizująca – wskazania, wytyczne i nowe kierunki badań Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2018
Słowa kluczowe:
terapia resynchronizująca, CRT, blok lewej odnogi pęczka Hisa, niewydolność serca
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rokowanie w przewlekłej niewydolności serca jest nadal złe mimo istotnego postępu terapii, jaki dokonał się w ciągu ostatnich lat. Szeroki zespół QRS, w tym także blok lewej odnogi pęczka Hisa, istotnie pogarsza rokowanie pacjentów z przewlekłą niewydolnością serca. Terapia resynchronizująca jest podstawową niefarmakologiczną metodą leczenia pacjentów z objawową niewydolnością serca, obniżoną frakcją wyrzutową lewej komory i szerokim zespołem QRS. W niniejszym artykule przedstawiliśmy aktualne wskazania do implantacji układów do resynchronizacji serca, a także nowe kierunki badań.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Januszkiewicz , Łukasz, Załuska, R., & Grabowski , M. (2018). Terapia resynchronizująca – wskazania, wytyczne i nowe kierunki badań. Medycyna Faktów , 11(4(41), 314-319. https://doi.org/10.24292/01.MF.0418.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Savarese G., Lund L.H.: Global Public Health Burden of Heart Failure. Card. Fail. Rev. 2017; 3: 7-11.
2. Cei F., Fonseca C., Mota T. et al.; EPICA Investigators: Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 2002; 4: 531-539.
3. Heidenreuch P.A., Albert N.M., Allen L.A. et al.: Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ. Heart Fail. 2013; 6: 606-619.
4. Crespo-Leiro M.G., Anker S.D., Maggioni A.P. et al.: European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur. J. Heart Fail. 2016; 18: 613-625.
5. Kashani A., Barold S.S.: Significance of QRS Complex Duration in Patients With Heart Failure. J. Am. Coll. Cardiol. 2005; 46: 2183-2192.
6. Clark A.L., Goode K., Cleland J.G.F.: The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur. J. Heart Fail. 2008; 10: 696-702.
7. Neeland I.J., Kontos M.C., de Lemos J.A.: Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. J. Am. Coll. Cardiol. 2012; 60: 96-105.
8. Auricchio A., Fantoni C., Regoli F. et al.: Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004; 109: 1133-1139.
9. Francia P., Balla C., Paneni F. et al.: Left bundle-branch block–pathophysiology, prognosis, and clinical management. Clin. Cardiol. 2007; 30: 110-115.
10. Brignole M., Auricchio A., Baron-Esquivias G. et al.: 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur. Heart J. 2013; 34: 2281-2329.
11. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
12. Kusumoto F.M., Schoenfeld M.H., Barrett C. et al.: 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. Heart Rhythm 2018. DOI: 10.1016/j.hrthm.2018.10.037.
13. Epstein A.E., DiMarco J.P., Ellenbogen K.A. et al.: 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. J. Am. Coll. Cardiol. 2013; 61: e6-75.
14. Strauss D.G., Selvester R.H., Wagner G.S.: Defining left bundle branch block in the era of cardiac resynchronization therapy. Am. J. Cardiol. 2011; 107: 927-934.
15. Willems J.L., Robles de Medina E.O., Bernard E.O. et al.: Criteria for interventricular conduction disturbances and preexcitation. World Health Organizational/International Society and Federation for Cardiology Task Force Ad Hoc. J. Am. Coll. Cardiol. 1985; 5: 1261-1275.
16. Normand C., Linde C., Singh J., Dickstein K.: Indications for Cardiac Resynchronization Therapy. A Comparison of the Major International Guidelines. JACC Heart Fail. 2018; 6: 308-316.
17. Ruschitzka F., Abraham W.T., Singh J.P. et al.: Cardiac resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 2013; 369: 1395-1405.
18. Brugada J., Delnoy P.P., Brachmann J. et al.: Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur. Heart J. 2017; 38: 730-738.
19. Khidir M.J.H., Delgado V., Marsan N.A. et al.: QRS duration versus morphology and survival after cardiac resynchronization therapy. ESC Heart Fail. 2017; 4: 23-30.
20. Cleland J.G., Abraham W.T., Linde C. et al.: An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur. Heart J. 2013; 34: 3547-3556.
21. Poole J.E., Singh J.P., Birgersdotter-Green U.: QRS Duration or QRS Morphology: What Really Matters in Cardiac Resynchronization Therapy? J. Am. Coll. Cardiol. 2016; 67: 1104-1117.
22. Vancura V., Wichterle D., Ulc I. et al.: The variability of automated QRS duration measurement. Europace 2017; 19: 636-643.
23. Januszkiewicz Ł., Vegh E., Borgquist R. et al.: Prognostic implication of baseline PR interval in cardiac resynchronization therapy recipients. Heart Rhythm 2015; 12: 2256-2262.
24. Maass A.H., Vernooy K., Wijers S.C. et al.: Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. Europace 2018; 20: e1-e10.
25. Tereshchenko L.G., Cheng A., Park J. et al.: Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm 2015; 12: 2402-2410.
26. Barsheshet A., Goldenberg I., Moss A.J. et al.: Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur. Heart J. 2011; 32: 1622-1630.
27. Chatterjee N.A., Roka A., Lubitz S.A. et al.: Reduced appropriate implantable-cardioverter therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur. Heart J. 2015; 36: 2780-2799.
28. Singh J.P., Klein H.U., Huang D.T. et al.: Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011; 123: 1159-1166.
29. Kutyifa V., Kosztin A., Klein H.U. et al.: Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC Clin. Electrophysiol. 2018; 4: 1410-1420.
30. Gold M.R., Yu Y., Singh J.P. et al.: The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm 2013; 10: 988-993.
31. Adelstein E.C., Saba S.: Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am. Heart J. 2007; 153: 105-112.
32. Boriani G., Connors S., Kalarus Z. et al.: Cardiac Resynchronization Therapy With a Quadripolar Electrode Lead Decreases Complications at 6 Months: Results of the MORE-CRT Randomized Trial. JACC Clin. Electrophysiol. 2016; 2: 212-220.
33. Forleo G.B., Santini L., Giammaria M. et al.: Multipoint pacing via a quadripolar left-ventricular lead: preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP). Europace 2017; 19: 1170-1177.
34. Mazurek M., Jędrzejczyk-Patej E., Lenarczyk R. et al.: Do we need to monitor the percentage of biventricular pacing day by day? Int. J. Cardiol. 2016; 221: 81-89.
35. Daubert C., Behar N., Martins R.P. et al.: Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur. Heart J. 2017; 38: 1463-1472.
36. Birnie D., Lemke B., Aonuma K. et al.: Clinical outcomes with synchronization left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm 2013; 10: 1368-1374.
37. Altman R.K., Parks K.A., Schlett C.L. et al.: Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur. Heart J. 2012; 33: 2181-2188.
38. Biffi M., Defaye P., Jais P. et al.: Benefits of left ventricular endocardial pacing comparing failed implants and prior non-responders to conventional cardiac resynchronization therapy: A subanalysis from the ALSYNC study. Int. J. Cardiol. 2018; 259: 88-93.
39. Reddy V.Y., Miller M.A., Neuzil P. et al.: Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study. J. Am. Coll. Cardiol. 2017; 69: 2119-2129.
40. Mafi-Rad M., Luermans J.G., Blaauw Y. et al.: Feasibility and Acute Hemodynamic Effect of Left Ventricular Septal Pacing by Transvenous Approach Through the Interventricular Septum. Circ. Arrhythm. Electrophysiol. 2016; 9: e003344.
41. Sharma P.S., Dandamudi G., Herweg B. et al.: Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: A multicenter experience. Heart Rhythm 2018; 15: 413-420.
42. Merkely B., Kosztin A., Roka A. et al.: Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace 2017; 19: 1549-1555.
43. ClinicalTrails.gov. CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). Dostęp 25.11.2018 r.
2. Cei F., Fonseca C., Mota T. et al.; EPICA Investigators: Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 2002; 4: 531-539.
3. Heidenreuch P.A., Albert N.M., Allen L.A. et al.: Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ. Heart Fail. 2013; 6: 606-619.
4. Crespo-Leiro M.G., Anker S.D., Maggioni A.P. et al.: European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur. J. Heart Fail. 2016; 18: 613-625.
5. Kashani A., Barold S.S.: Significance of QRS Complex Duration in Patients With Heart Failure. J. Am. Coll. Cardiol. 2005; 46: 2183-2192.
6. Clark A.L., Goode K., Cleland J.G.F.: The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur. J. Heart Fail. 2008; 10: 696-702.
7. Neeland I.J., Kontos M.C., de Lemos J.A.: Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. J. Am. Coll. Cardiol. 2012; 60: 96-105.
8. Auricchio A., Fantoni C., Regoli F. et al.: Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004; 109: 1133-1139.
9. Francia P., Balla C., Paneni F. et al.: Left bundle-branch block–pathophysiology, prognosis, and clinical management. Clin. Cardiol. 2007; 30: 110-115.
10. Brignole M., Auricchio A., Baron-Esquivias G. et al.: 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur. Heart J. 2013; 34: 2281-2329.
11. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
12. Kusumoto F.M., Schoenfeld M.H., Barrett C. et al.: 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. Heart Rhythm 2018. DOI: 10.1016/j.hrthm.2018.10.037.
13. Epstein A.E., DiMarco J.P., Ellenbogen K.A. et al.: 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. J. Am. Coll. Cardiol. 2013; 61: e6-75.
14. Strauss D.G., Selvester R.H., Wagner G.S.: Defining left bundle branch block in the era of cardiac resynchronization therapy. Am. J. Cardiol. 2011; 107: 927-934.
15. Willems J.L., Robles de Medina E.O., Bernard E.O. et al.: Criteria for interventricular conduction disturbances and preexcitation. World Health Organizational/International Society and Federation for Cardiology Task Force Ad Hoc. J. Am. Coll. Cardiol. 1985; 5: 1261-1275.
16. Normand C., Linde C., Singh J., Dickstein K.: Indications for Cardiac Resynchronization Therapy. A Comparison of the Major International Guidelines. JACC Heart Fail. 2018; 6: 308-316.
17. Ruschitzka F., Abraham W.T., Singh J.P. et al.: Cardiac resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 2013; 369: 1395-1405.
18. Brugada J., Delnoy P.P., Brachmann J. et al.: Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur. Heart J. 2017; 38: 730-738.
19. Khidir M.J.H., Delgado V., Marsan N.A. et al.: QRS duration versus morphology and survival after cardiac resynchronization therapy. ESC Heart Fail. 2017; 4: 23-30.
20. Cleland J.G., Abraham W.T., Linde C. et al.: An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur. Heart J. 2013; 34: 3547-3556.
21. Poole J.E., Singh J.P., Birgersdotter-Green U.: QRS Duration or QRS Morphology: What Really Matters in Cardiac Resynchronization Therapy? J. Am. Coll. Cardiol. 2016; 67: 1104-1117.
22. Vancura V., Wichterle D., Ulc I. et al.: The variability of automated QRS duration measurement. Europace 2017; 19: 636-643.
23. Januszkiewicz Ł., Vegh E., Borgquist R. et al.: Prognostic implication of baseline PR interval in cardiac resynchronization therapy recipients. Heart Rhythm 2015; 12: 2256-2262.
24. Maass A.H., Vernooy K., Wijers S.C. et al.: Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. Europace 2018; 20: e1-e10.
25. Tereshchenko L.G., Cheng A., Park J. et al.: Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm 2015; 12: 2402-2410.
26. Barsheshet A., Goldenberg I., Moss A.J. et al.: Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur. Heart J. 2011; 32: 1622-1630.
27. Chatterjee N.A., Roka A., Lubitz S.A. et al.: Reduced appropriate implantable-cardioverter therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur. Heart J. 2015; 36: 2780-2799.
28. Singh J.P., Klein H.U., Huang D.T. et al.: Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011; 123: 1159-1166.
29. Kutyifa V., Kosztin A., Klein H.U. et al.: Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC Clin. Electrophysiol. 2018; 4: 1410-1420.
30. Gold M.R., Yu Y., Singh J.P. et al.: The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm 2013; 10: 988-993.
31. Adelstein E.C., Saba S.: Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am. Heart J. 2007; 153: 105-112.
32. Boriani G., Connors S., Kalarus Z. et al.: Cardiac Resynchronization Therapy With a Quadripolar Electrode Lead Decreases Complications at 6 Months: Results of the MORE-CRT Randomized Trial. JACC Clin. Electrophysiol. 2016; 2: 212-220.
33. Forleo G.B., Santini L., Giammaria M. et al.: Multipoint pacing via a quadripolar left-ventricular lead: preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP). Europace 2017; 19: 1170-1177.
34. Mazurek M., Jędrzejczyk-Patej E., Lenarczyk R. et al.: Do we need to monitor the percentage of biventricular pacing day by day? Int. J. Cardiol. 2016; 221: 81-89.
35. Daubert C., Behar N., Martins R.P. et al.: Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur. Heart J. 2017; 38: 1463-1472.
36. Birnie D., Lemke B., Aonuma K. et al.: Clinical outcomes with synchronization left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm 2013; 10: 1368-1374.
37. Altman R.K., Parks K.A., Schlett C.L. et al.: Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur. Heart J. 2012; 33: 2181-2188.
38. Biffi M., Defaye P., Jais P. et al.: Benefits of left ventricular endocardial pacing comparing failed implants and prior non-responders to conventional cardiac resynchronization therapy: A subanalysis from the ALSYNC study. Int. J. Cardiol. 2018; 259: 88-93.
39. Reddy V.Y., Miller M.A., Neuzil P. et al.: Cardiac Resynchronization Therapy With Wireless Left Ventricular Endocardial Pacing: The SELECT-LV Study. J. Am. Coll. Cardiol. 2017; 69: 2119-2129.
40. Mafi-Rad M., Luermans J.G., Blaauw Y. et al.: Feasibility and Acute Hemodynamic Effect of Left Ventricular Septal Pacing by Transvenous Approach Through the Interventricular Septum. Circ. Arrhythm. Electrophysiol. 2016; 9: e003344.
41. Sharma P.S., Dandamudi G., Herweg B. et al.: Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: A multicenter experience. Heart Rhythm 2018; 15: 413-420.
42. Merkely B., Kosztin A., Roka A. et al.: Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace 2017; 19: 1549-1555.
43. ClinicalTrails.gov. CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). Dostęp 25.11.2018 r.